Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Röth A, Broome CM, Barcellini W, Jilma B, Hill QA, Cella D, Tvedt THA, Yamaguchi M, Lee M, Shafer F, Wardęcki M, Jiang X, Patel P, Joly F, Weitz IC. Röth A, et al. Among authors: shafer f. Eur J Haematol. 2023 Mar;110(3):280-288. doi: 10.1111/ejh.13903. Epub 2022 Dec 9. Eur J Haematol. 2023. PMID: 36403132 Clinical Trial.
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Yoo R, Jayawardene D, Vagge DS, Kralova K, Shafer F, Wardȩcki M, Lee M, Berentsen S. Röth A, et al. Among authors: shafer f. Am J Hematol. 2023 Aug;98(8):1246-1253. doi: 10.1002/ajh.26965. Epub 2023 May 29. Am J Hematol. 2023. PMID: 37246953
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Among authors: shafer f. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Roth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Patel P, Jiang X, Reuter C, Su J, Shafer F, Lee M, Berentsen S. Roth A, et al. Among authors: shafer f. Haematologica. 2022 Jul 1;107(7):1698-1702. doi: 10.3324/haematol.2021.279812. Haematologica. 2022. PMID: 35172561 Free PMC article. No abstract available.
Laboratory variability in the diagnosis of type 2 VWD variants.
DiGiandomenico S, Christopherson PA, Haberichter SL, Abshire TC, Montgomery RR, Flood VH; Zimmerman Program Investigators. DiGiandomenico S, et al. J Thromb Haemost. 2021 Jan;19(1):131-138. doi: 10.1111/jth.15129. Epub 2020 Nov 10. J Thromb Haemost. 2021. PMID: 33049112 Free PMC article.
41 results